Colorectal Neoplasms, Gastrointestinal Neoplasms, Neoplasms, Rectal Diseases
Conditions
Keywords
Imaging, Magnetic Resonance, Rectal Cancer, Apoptosis, Proliferation, Cancer, Tissue Study
Brief summary
This study tests biopsy and tissue from patients who have been treated for primary rectal cancer at the Royal Marsden Hospital between 2011 and 2013, who have an mrTRG score at post-chemoradiotherapy MRI. It is a retrospective pilot study to determine the apoptotic and proliferative index count pre and post chemoradiotherapy.
Detailed description
The investigators hope to validate the apoptotic and proliferative index as a predictive response marker and lend support to mrTRG as a putative prognostic tool in the treatment pathway for rectal cancer patients. Even though this is a retrospective study, the investigators hope that pre-treatment apoptotic and proliferative scores will correlate to post treatment response and mrTRG scores. In doing so, the investigators can predict how patients will respond to treatment from initial diagnostic biopsies and foresee a patients individual treatment plan.
Interventions
None listed
Sponsors
The Royal College of Surgeons of England
Croydon Health Services NHS Trust
Royal Marsden NHS Foundation Trust
Study design
Observational model
COHORT
Time perspective
RETROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Patients over 18 years of age. * Patients with primary adenocarcinoma of the rectum (diagnosed on tissue biopsy and disease spread assessed on CT and MRI). * Tumours must be considered sufficiently high-risk to require pre-operative chemoradiotherapy followed by surgery. * Patients must have had a pre- and post-treatment MRI scan of the rectum and pelvis. * We must have access to stored tissue for each patient
Exclusion criteria
* No pre-operative radiotherapy * Patients with synchronous tumours * Patients under the age of 18 years
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Apoptotic index, Ki67 and Geminin in cells per mm cubed from diognostic biopsy | Tissue removed at diagnosis (approximately 15 weeks prior to surgery) | Tissue biopsy taken at endoscopy to confirm cancer diagnosis is studied |
| Apoptotic index, Ki67 and Geminin in cells per mm cubed from resected tumour | Tissue removed during operation | Tissue removed during surgery (to resect tumour) is studied |
Secondary
| Measure | Time frame |
|---|---|
| Time to local recurrence | At one and three years |
| Disease Free Survival (DFS) | At one and three years |
| Overall Survival (OS) | At one and three years |
Countries
United Kingdom
Outcome results
None listed